A Phase 3 interventional study of Durvalumab and Cisplatin in Extensive-stage Small Cell Lung Cancer, sponsored by AstraZeneca. Completed at 35 sites in 6 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-05-23.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing durvalumab in Small Cell Lung Carcinoma — 10 open to participants now, 19 under way, 3 of them phase 3. durvalumab · Small Cell Lung Carcinoma.
Among the 36 studies testing durvalumab in Small Cell Lung Carcinoma, this one is the 5th largest by enrollment, is one of 7 that started in 2021, is one of 6 in phase 3, and was the 15th registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →10 of the 36 studies testing durvalumab in Small Cell Lung Carcinoma are open now, in 8 countries. Recruiting first, the newest first:
Jazz Pharmaceuticals · Sites in United States
Ages 18+
Bindu R Potugari · Sites in United States
Ages 18+
AstraZeneca · Sites in Australia, Georgia, Poland and 2 more countries
Ages 18+
Qian Chu · Sites in China
Ages 18+
Alliance Foundation Trials, LLC. · Sites in United States
Ages 18+
By country, each count listing its studies:
durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, durvalumab is the treatment under test here. Read study by study →
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 6
First in 2016; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 152 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 50 across the 36 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 36 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
25 studies in Small Cell Lung Carcinoma by AstraZeneca: 3 open now, 10 under way, 3 of them phase 3. Of 15 finished, 4 (27%) have results posted.
Among the 25 studies in Small Cell Lung Carcinoma by AstraZeneca, this one is the 5th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2021, is one of 6 in phase 3, and was the 16th registered.
AstraZeneca’s Small Cell Lung Carcinoma studies by the year they started, since 2004.
5 of the studies testing durvalumab in Small Cell Lung Carcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05856695Intergroupe Francophone de Cancerologie ThoraciqueDurvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC) | 2026-11 |
| NCT06223711Universität des SaarlandesDurvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC | 2027-03 |
| NCT07391670AstraZenecaA Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab | 2027-08-30 |
| NCT05796089Trans Tasman Radiation Oncology GroupChemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy | 2027-09-30 |
| NCT05068232University of ChicagoDurvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 36 studies testing durvalumab in Small Cell Lung Carcinoma, from their registry updates:
Among AstraZeneca’s 25 in Small Cell Lung Carcinoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer.
The study will be conducted in North America, Europe and Turkey.
In this single arm study participants will be treated with with durvalumab alone and concurrently with platinum-based chemotherapy and etoposide during the study period until radiological disease progression, unless there is clinical progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met, as per investigator assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of another primary except for:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive durvalumab dose A administered via intravenous (IV) infusion concurrently with platinum-based chemotherapy and etoposide every 3 weeks (q3w). Thereafter, durvalumab monotherapy will be continued every 4 weeks post-chemotherapy unless specific treatment discontinuation criteria are met.
Drug: Durvalumab · Drug: Cisplatin · Drug: Carboplatin · Drug: Etoposide
Participants will receive durvalumab via IV infusion on Day 1 of each cycle.
Participants will receive cisplatin via IV administration on Day 1 of each cycle.
Participants will receive carboplatin via IV administration Day 1 of each cycle.
Participants will receive etoposide via IV administration on days 1 to 3 of each cycle.
Number of Participants With Incidence of Grade 3 or Higher Adverse Events (AEs)
Incidence of Grade 3 or higher adverse events to evaluate safety and tolerability profile of durvalumab + Platinum (cisplatin or carboplatin) plus etoposide (EP) treatment was assessed.
Time frame: From first dose of study treatment until 90 days after treatment discontinuation, up to 2.5 years.
Number of Participants With Incidence of Immune Mediated Adverse Events (imAEs)
Immune mediated adverse events (imAEs) were assessed to evaluate safety and tolerability profile of durvalumab + EP treatment. An imAE is defined as an AESI that is associated with drug exposure and is consistent with an immune-mediated mechanism of action (MOA) and where there is no clear alternate etiology.
Time frame: From first dose of study treatment until 90 days after treatment discontinuation, up to 2.5 years.
Progression-free Survival (PFS)
Efficacy of durvalumab + EP treatment by evaluating PFS according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) was assessed. The PFS is the time from the first date of treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from Investigational medicinal product (IMP) or received another anticancer therapy prior to progression.
Time frame: From first dose of study treatment until disease progression or death, up to 2.5 years.
Percentage of Participants Alive and Progression-free at 12 Months From First Date of Treatment (PFS12)
The efficacy of durvalumab + EP treatment by evaluating PFS12 according to RECIST 1.1 was assessed.
Time frame: From first date of study treatment until 12 months.
Objective Response Rate (ORR)
The efficacy of durvalumab + EP treatment by evaluating ORR according to RECIST 1.1 was assessed. The ORR will be assessed based on Investigator-assessed response to treatment of complete response (CR) and partial response (PR), per RECIST1.1.
Time frame: From screening until disease progression or the last evaluable assessment in the absence of progression, up to 2.5 years.
Duration of Response (DoR)
The efficacy of durvalumab + EP treatment by evaluating DoR according to RECIST 1.1 was assessed. The DoR is time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression.
Time frame: From the date of first documented response until the first date of documented progression or death in the absence of disease progression, up to 2.5 years.
Percentage of Participants Remaining in Response, 12 Months After First Documented Objective Response (DoR12)
The efficacy of durvalumab + EP treatment by evaluating DoR12 according to RECIST 1.1 was assessed.
Time frame: From the date of first documented response until the first date of documented progression or death in the absence of disease progression, up to 2.5 years.
Overall Survival (OS)
Assessment of the efficacy of durvalumab + EP treatment by evaluating OS. The OS is the time from the first date of treatment until death due to any cause.
Time frame: From first dose of study treatment to death, up to 2.5 years.
Percentage of Participants Alive at 12 Months From First Date of Treatment (OS12)
The efficacy of durvalumab + EP treatment by evaluating OS12 was assessed.
Time frame: From first dose of study treatment till 12 months.
Number of Participants With Adverse Events and Serious Adverse Events
To evaluate safety and tolerability profile of durvalumab + EP treatment, adverse events and serious adverse events were assessed.
Time frame: From first dose of study treatment until 90 days after discontinuation, up to 2.5 years.
Number of Participants With Adverse Events of Special Interests
To evaluate safety and tolerability profile of durvalumab + EP treatment, adverse events of special interests were assessed. An AESI is an AE of scientific and medical interest specific to understanding of the IMP. AESIs for durvalumab include, but are not limited to, events with a potential inflammatory or immune-mediated mechanism and which may require more frequent monitoring and/or interventions such as steroids, immunosuppressants, and/or hormone replacement therapy. This includes adverse events of special/ possible interest.
Time frame: From first dose of study treatment until 90 days after discontinuation, up to 2.5 years.
The study was conducted at 32 sites in 5 countries: Bulgaria, Czech Republic, Germany, Italy, Turkey. Study results are presented as of final data cut-off (DCO), 21Apr2024. After final DCO, no additional data was collected for the purpose of the analysis. Participants were allowed to continue the study drug until other drug supply options were available. The last subject's last visit was declared on 2Jan2025 once all participants were transferred to a rollover study or marketed product.
| Milestone | Durvalumab - (Cisplatin or Carboplatin) - Etoposide (Durvalumab +EP) |
|---|---|
| Started | 152 |
| Completed | 152 |
| Not completed | 0 |
Incidence of Grade 3 or higher adverse events to evaluate safety and tolerability profile of durvalumab + Platinum (cisplatin or carboplatin) plus etoposide (EP) treatment was assessed.
| Participants | Durvalumab+EP |
|---|---|
| Number of Participants With Incidence of Grade 3 or Higher Adverse Events (AEs) | 91 |
Immune mediated adverse events (imAEs) were assessed to evaluate safety and tolerability profile of durvalumab + EP treatment. An imAE is defined as an AESI that is associated with drug exposure and is consistent with an immune-mediated mechanism of action (MOA) and where there is no clear alternate etiology.
| Participants | Durvalumab+EP |
|---|---|
| Number of Participants With Incidence of Immune Mediated Adverse Events (imAEs) | 22 |
Efficacy of durvalumab + EP treatment by evaluating PFS according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) was assessed. The PFS is the time from the first date of treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from Investigational medicinal product (IMP) or received another anticancer therapy prior to progression.
| Months | Durvalumab+EP |
|---|---|
| Progression-free Survival (PFS) | 6.3 (5.75 to 6.47) |
The efficacy of durvalumab + EP treatment by evaluating PFS12 according to RECIST 1.1 was assessed.
| Percentage of participants | Durvalumab+EP |
|---|---|
| Percentage of Participants Alive and Progression-free at 12 Months From First Date of Treatment (PFS12) | 15.0 (9.76 to 21.21) |
The efficacy of durvalumab + EP treatment by evaluating ORR according to RECIST 1.1 was assessed. The ORR will be assessed based on Investigator-assessed response to treatment of complete response (CR) and partial response (PR), per RECIST1.1.
| Percentage of participants | Durvalumab+EP |
|---|---|
| Objective Response Rate (ORR) | 66.4 (58.3 to 73.9) |
The efficacy of durvalumab + EP treatment by evaluating DoR according to RECIST 1.1 was assessed. The DoR is time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression.
| Months | Durvalumab+EP |
|---|---|
| Duration of Response (DoR) | 5.2 (5.03 to 5.59) |
The efficacy of durvalumab + EP treatment by evaluating DoR12 according to RECIST 1.1 was assessed.
| Percentage of participants | Durvalumab+EP |
|---|---|
| Percentage of Participants Remaining in Response, 12 Months After First Documented Objective Response (DoR12) | 19.8 (12.70 to 28.06) |
Assessment of the efficacy of durvalumab + EP treatment by evaluating OS. The OS is the time from the first date of treatment until death due to any cause.
| Months | Durvalumab+EP |
|---|---|
| Overall Survival (OS) | 16.4 (12.45 to 18.73) |
The efficacy of durvalumab + EP treatment by evaluating OS12 was assessed.
| Percentage of participants | Durvalumab+EP |
|---|---|
| Percentage of Participants Alive at 12 Months From First Date of Treatment (OS12) | 59.8 (51.00 to 67.55) |
To evaluate safety and tolerability profile of durvalumab + EP treatment, adverse events and serious adverse events were assessed.
| Participants | Durvalumab+EP |
|---|---|
| Any Adverse event (AE) | 142 |
| Any AE possibly related to any treatment | 109 |
| Any AE of maximum CTCAE grade 3 or grade 4 | 85 |
| Any AE of maximum CTCAE grade 3 or grade 4, possibly related to any treatment | 59 |
| Any AE with outcome of death | 15 |
| Any AE with outcome of death, possibly related to any treatment | 4 |
| Any AE with outcome of death, possibly related to durvalumab | 0 |
| Any AE with outcome of death, possibly related to EP | 4 |
| Any SAE (including events with outcome of death) | 52 |
| Any SAE (including events with outcome of death), possibly related to any treatment | 16 |
| Any AE leading to interruption or discontinuation of durvalumab | 40 |
| Any AE leading to interruption or discontinuation of EP | 41 |
To evaluate safety and tolerability profile of durvalumab + EP treatment, adverse events of special interests were assessed. An AESI is an AE of scientific and medical interest specific to understanding of the IMP. AESIs for durvalumab include, but are not limited to, events with a potential inflammatory or immune-mediated mechanism and which may require more frequent monitoring and/or interventions such as steroids, immunosuppressants, and/or hormone replacement therapy. This includes adverse events of special/ possible interest.
| Participants | Durvalumab+EP |
|---|---|
| Number of Participants With Adverse Events of Special Interests | 82 |
Collected over From first dose of study treatment until 90 days after treatment discontinuation, up to 2.5 years.. Non-serious events are listed at a 0.03% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Durvalumab+EP | 85/152 (55.9%) | 52/152 (34.2%) | 136/152 (89.5%) |
| Event | Durvalumab+EP |
|---|---|
| PneumoniaInfections and infestations | 9/152 |
| HyponatraemiaMetabolism and nutrition disorders | 4/152 |
| Acute kidney injuryRenal and urinary disorders | 4/152 |
| AnaemiaBlood and lymphatic system disorders | 3/152 |
| LeukopeniaBlood and lymphatic system disorders | 3/152 |
| HyperglycaemiaMetabolism and nutrition disorders | 3/152 |
| Abdominal pain upperGastrointestinal disorders | 3/152 |
| Platelet count decreasedInvestigations | 3/152 |
| SepsisInfections and infestations | 2/152 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/152 |
| Event | Durvalumab+EP |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 85/152 |
| NeutropeniaBlood and lymphatic system disorders | 51/152 |
| NauseaGastrointestinal disorders | 37/152 |
| ConstipationGastrointestinal disorders | 30/152 |
| ThrombocytopeniaBlood and lymphatic system disorders | 24/152 |
| FatigueGeneral disorders | 24/152 |
| AlopeciaSkin and subcutaneous tissue disorders | 20/152 |
| LeukopeniaBlood and lymphatic system disorders | 19/152 |
| HypomagnesaemiaMetabolism and nutrition disorders | 19/152 |
| HyperthyroidismEndocrine disorders | 18/152 |
Safety analysis set (SAF) which consisted of all enrolled patients who received at least 1 dose of any study treatment.
| Age, Continuous(Years) | Durvalumab +EP |
|---|---|
| Median | 64.0 (27 to 83) |
| Sex: Female, Male(Participants) | Durvalumab +EP |
|---|---|
| Female | 54 |
| Male | 98 |
| Race/Ethnicity, Customized(Participants) | Durvalumab +EP |
|---|---|
| White | 151 |
| Other | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Nov 2021 to primary completion in Jun 2023, 19 months.
Results were first posted in Aug 2024, 1 year 2 months after primary completion.
Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 19 months is below that.
Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Durvalumab · Etoposide